Two Point Capital Management Inc. Buys 90 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Two Point Capital Management Inc. boosted its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.8% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 11,881 shares of the medical research company’s stock after purchasing an additional 90 shares during the quarter. Thermo Fisher Scientific accounts for about 2.9% of Two Point Capital Management Inc.’s investment portfolio, making the stock its 19th biggest holding. Two Point Capital Management Inc.’s holdings in Thermo Fisher Scientific were worth $6,306,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Sugarloaf Wealth Management LLC increased its stake in Thermo Fisher Scientific by 6.9% in the 4th quarter. Sugarloaf Wealth Management LLC now owns 294 shares of the medical research company’s stock worth $156,000 after acquiring an additional 19 shares during the last quarter. Rosenberg Matthew Hamilton increased its stake in Thermo Fisher Scientific by 3.7% in the 4th quarter. Rosenberg Matthew Hamilton now owns 526 shares of the medical research company’s stock worth $279,000 after acquiring an additional 19 shares during the last quarter. Tsfg LLC increased its stake in Thermo Fisher Scientific by 8.3% in the 4th quarter. Tsfg LLC now owns 249 shares of the medical research company’s stock worth $132,000 after acquiring an additional 19 shares during the last quarter. Pacifica Partners Inc. increased its stake in Thermo Fisher Scientific by 16.5% in the 4th quarter. Pacifica Partners Inc. now owns 141 shares of the medical research company’s stock worth $69,000 after acquiring an additional 20 shares during the last quarter. Finally, Retirement Planning Group LLC increased its stake in Thermo Fisher Scientific by 4.9% in the 4th quarter. Retirement Planning Group LLC now owns 446 shares of the medical research company’s stock worth $237,000 after acquiring an additional 21 shares during the last quarter. 89.23% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

TMO has been the topic of several recent research reports. Sanford C. Bernstein reiterated a “market perform” rating on shares of Thermo Fisher Scientific in a research report on Monday, January 8th. Barclays raised their price target on Thermo Fisher Scientific from $590.00 to $615.00 and gave the stock an “equal weight” rating in a research report on Thursday. Robert W. Baird reduced their price target on Thermo Fisher Scientific from $621.00 to $620.00 and set an “outperform” rating on the stock in a research report on Thursday. HSBC increased their price objective on Thermo Fisher Scientific from $630.00 to $660.00 and gave the stock a “buy” rating in a report on Wednesday, April 17th. Finally, Deutsche Bank Aktiengesellschaft lifted their target price on Thermo Fisher Scientific from $600.00 to $610.00 and gave the company a “buy” rating in a research report on Thursday. Five investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $606.76.

Thermo Fisher Scientific Stock Up 0.2 %

Shares of TMO traded up $1.19 during midday trading on Friday, hitting $572.92. 952,310 shares of the company’s stock traded hands, compared to its average volume of 1,554,597. The company has a current ratio of 1.70, a quick ratio of 1.39 and a debt-to-equity ratio of 0.68. The firm’s fifty day moving average is $573.08 and its 200-day moving average is $529.36. Thermo Fisher Scientific Inc. has a 1 year low of $415.60 and a 1 year high of $603.82. The stock has a market capitalization of $218.69 billion, a price-to-earnings ratio of 36.70, a price-to-earnings-growth ratio of 2.44 and a beta of 0.80.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, April 24th. The medical research company reported $5.11 EPS for the quarter, beating analysts’ consensus estimates of $4.70 by $0.41. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. The firm had revenue of $10.35 billion for the quarter, compared to analysts’ expectations of $10.14 billion. As a group, sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 21.52 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, April 15th. Stockholders of record on Friday, March 15th were given a dividend of $0.39 per share. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. This represents a $1.56 annualized dividend and a dividend yield of 0.27%. The ex-dividend date of this dividend was Thursday, March 14th. Thermo Fisher Scientific’s payout ratio is 10.01%.

Insider Buying and Selling

In other news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $597.98, for a total value of $5,979,800.00. Following the completion of the sale, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at $74,039,491.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, CEO Marc N. Casper sold 5,547 shares of the firm’s stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $550.62, for a total value of $3,054,289.14. Following the transaction, the chief executive officer now directly owns 43,608 shares in the company, valued at approximately $24,011,436.96. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $597.98, for a total value of $5,979,800.00. Following the completion of the transaction, the chief executive officer now owns 123,816 shares in the company, valued at $74,039,491.68. The disclosure for this sale can be found here. Insiders have sold 50,277 shares of company stock worth $28,513,384 in the last quarter. 0.32% of the stock is owned by insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.